All Stories

  1. Expert consensus on the role of immunotherapy in nasopharyngeal carcinoma: clinical and economic perspectives from the GCC region

    Article • Expert Review of Anticancer Therapy, May 2026, Taylor & Francis

    Assoc. Prof Shereen Elazzazy

  2. CLO26-124: Comparative Outcomes of CDK4/6 Inhibitors and Endocrine Therapy in HER2-Low Versus HER2-Negative Metastatic Breast Cancer: A Retrospective Nationwide Cohort Study From Qatar

    Article • Journal of the National Comprehensive Cancer Network, March 2026, Harborside Press, LLC

    Assoc. Prof Shereen Elazzazy

  3. Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis

    Article • Journal of Pharmaceutical Policy and Practice, February 2026, Taylor & Francis

    Professor Mohamed Izham Mohamed Ibrahim, Assoc. Prof Shereen Elazzazy

  4. EE330 Dihydropyrimidine Dehydrogenase (DPYD) Genetic Testing Before Fluoropyrimidine-Based Adjuvant Chemotherapy for Colorectal Cancer in Qatar: A Cost-Effective Approach

    Article • Value in Health, December 2025, Elsevier

    Assoc. Prof Shereen Elazzazy

  5. EE430 Evaluating Cost Benefits of Subcutaneous vs. Intravenous Trastuzumab/Pertuzumab in HER2-Positive Early Breast Cancer Patients: From Qatari Healthcare Perspective

    Article • Value in Health, December 2025, Elsevier

    Assoc. Prof Shereen Elazzazy

  6. Healthcare Providers' knowledge and attitudes toward venous thromboembolism prophylaxis in multiple myeloma: A cross-sectional survey

    Article • Blood, November 2025, American Society of Hematology

    Assoc. Prof Shereen Elazzazy

  7. Real-world descriptive analysis of the use of bispecific t cell engagers (BiTEs) in the treatment of hematological malignancies in Qatar: A state-wide retrospective cohort study

    Article • Blood, November 2025, American Society of Hematology

    Assoc. Prof Shereen Elazzazy

  8. Real-world safety and discontinuation patterns of ibrutinib in B-cell malignancies: A 9-year experience from Qatar

    Article • Blood, November 2025, American Society of Hematology

    Assoc. Prof Shereen Elazzazy

  9. Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

    Article • Frontiers in Immunology, October 2025, Frontiers

    Assoc. Prof Shereen Elazzazy , Dr. Mohamed Omar Saad

  10. Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness Analysis

    Article • Clinical Drug Investigation, January 2025, Springer Science + Business Media

    Assoc. Prof Shereen Elazzazy

  11. 577P A real-world analysis of immune checkpoint inhibitors outcomes in patients with baseline auto-immune diseases

    Article • Annals of Oncology, December 2024, Elsevier

    Dr. Mohamed Omar Saad, Assoc. Prof Shereen Elazzazy

  12. 571P The economic sequelae of immune related adverse events secondary to immune checkpoints inhibitors in Qatar: A hospital-perspective analysis

    Article • Annals of Oncology, December 2024, Elsevier

    Dr. Mohamed Omar Saad, Assoc. Prof Shereen Elazzazy

  13. Experience of Plerixafor Use for Autologous Stem Cell Mobilization in Qatar: A Single Center Experience

    Article • Blood, November 2024, American Society of Hematology

    Assoc. Prof Shereen Elazzazy

  14. HER2-low non-metastatic breast cancer in Qatar—a nationwide retrospective cohort study to evaluate the response to neoadjuvant chemotherapy: a real-world analysis

    Article • Frontiers in Oncology, October 2024, Frontiers

    Assoc. Prof Shereen Elazzazy

  15. Establishment of a clinical pharmacist-led multiple myeloma clinic with collaborative prescribing model at the national center for cancer care and research in Qatar

    Article • Journal of the American Pharmacists Association, September 2024, Elsevier

    Assoc. Prof Shereen Elazzazy

  16. Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation

    Article • Frontiers in Oncology, July 2024, Frontiers

    Assoc. Prof Shereen Elazzazy

  17. Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries

    Article • Journal of Health Economics and Outcomes Research, July 2024, Columbia Data Analytics

    Assoc. Prof Shereen Elazzazy

  18. Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries

    Article • Journal of Health Economics and Outcomes Research, July 2024, Columbia Data Analytics

    Assoc. Prof Shereen Elazzazy

  19. Abstract PO1-02-07: HER2 Low Non-Metastatic Breast Cancer in Qatar: A Nationwide Retrospective Cohort Study to Evaluate the Response to Neoadjuvant Chemotherapy: A Real-World Analysis

    Article • Cancer Research, May 2024, American Association for Cancer Research (AACR)

    Assoc. Prof Shereen Elazzazy

  20. Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non–Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study

    Article • Clinical Medicine Insights Oncology, January 2024, SAGE Publications

    Nabil E. Omar, Assoc. Prof Shereen Elazzazy

  21. The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study

    Article • Frontiers in Oncology, December 2023, Frontiers

    Assoc. Prof Shereen Elazzazy

  22. Establishment of a Clinical Pharmacist-Led Multiple Myeloma Clinic with Collaborative Prescribing Model at the National Center for Cancer Care and Research in Qatar

    Article • Blood, November 2023, American Society of Hematology

    Assoc. Prof Shereen Elazzazy

  23. Hematological Toxicity of Immune Checkpoint Inhibitors: Real-World Retrospective Outcomes from a Cohort Study in Qatar

    Article • Blood, November 2023, American Society of Hematology

    Assoc. Prof Shereen Elazzazy

  24. 50P A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis

    Article • Annals of Oncology, November 2023, Elsevier

    Assoc. Prof Shereen Elazzazy

  25. Late-Breaking Abstracts for MASCC/JASCC/ISOO Annual Meeting 2023

    Article • Supportive Care in Cancer, September 2023, Springer Science + Business Media

    Assoc. Prof Shereen Elazzazy

  26. 2023 ACCP Virtual Poster Symposium May 23 ‐ 24, 2023

    Article • JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, July 2023, Wiley

    Assoc. Prof Shereen Elazzazy

  27. Post‐COVID‐19‐associated multiorgan complications or “long COVID” with literature review and management strategy discussion: A meta‐analysis

    Article • Health Science Reports, April 2023, Wiley

    Nabil E. Omar, Assoc. Prof Shereen Elazzazy

  28. Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP)

    Article • BMC Health Services Research, January 2023, Springer Science + Business Media

    Assoc. Prof Shereen Elazzazy

  29. Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation

    Article • International Journal of Environmental Research and Public Health, December 2022, MDPI AG

    Professor Mohamed Izham Mohamed Ibrahim, Assoc. Prof Shereen Elazzazy

  30. Acknowledgement to Referees

    Article • Drugs & Therapy Perspectives, November 2022, Springer Science + Business Media

    Assoc. Prof Shereen Elazzazy

  31. Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP)

    Article • September 2022, Research Square

    Assoc. Prof Shereen Elazzazy

  32. Abstract P3-16-03: Clinical and pharmacoeconomic analyses of CDK4/6 inhibitors use in stage IV breast cancer females in the state of Qatar: A comparative retrospective observational study with cost effectiveness and cost utility analyses

    Article • Cancer Research, February 2022, American Association for Cancer Research (AACR)

    Assoc. Prof Shereen Elazzazy

  33. Mitotically active cellular fibroma of the ovary diagnosis and treatment

    Article • GSC Biological and Pharmaceutical Sciences, November 2021, GSC Online Press

    Assoc. Prof Shereen Elazzazy

  34. Long-term moderate to severe complications of COVID-19 infection since 2019 to date

    Article • Medicine Case Reports and Study Protocols, November 2021, Wolters Kluwer Health

    Assoc. Prof Shereen Elazzazy

  35. Assessment of Deep Vein Thrombosis (DVT) incidence among ambulatory cancer patients in Qatar: A retrospective cohort study

    Article • GSC Biological and Pharmaceutical Sciences, September 2021, GSC Online Press

    Assoc. Prof Shereen Elazzazy

  36. Abstracts for MASCC/ISOO Annual Meeting 2021

    Article • Supportive Care in Cancer, June 2021, Springer Science + Business Media

    Dr. Bashir Alsiddig Yousef, Assoc. Prof Shereen Elazzazy

  37. Chinese Herbal Medicine for Reducing Chemotherapy-Associated Side-Effects in Breast Cancer Patients: A Systematic Review and Meta-Analysis

    Article • Frontiers in Oncology, December 2020, Frontiers

    Assoc. Prof Shereen Elazzazy

  38. Breast Subtypes and Prognosis of Breast Cancer Patients With Initial Bone Metastasis: A Population-Based Study

    Article • Frontiers in Oncology, December 2020, Frontiers

    Assoc. Prof Shereen Elazzazy

  39. Acknowledgement to referees

    Article • Drugs & Therapy Perspectives, November 2020, Springer Science + Business Media

    Assoc. Prof Shereen Elazzazy

  40. Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review

    Article • Frontiers in Immunology, October 2020, Frontiers

    Nabil E. Omar, Dr Dina Johar, Assoc. Prof Shereen Elazzazy

  41. Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review

    Article • Medical Oncology, October 2020, Springer Science + Business Media

    Nabil E. Omar, Assoc. Prof Shereen Elazzazy

  42. Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial

    Article • Frontiers in Oncology, October 2020, Frontiers

    Assoc. Prof Shereen Elazzazy

  43. Timing of Chemotherapy and Radiotherapy Following Breast-Conserving Surgery for Early-Stage Breast Cancer: A Retrospective Analysis

    Article • Frontiers in Oncology, September 2020, Frontiers

    Assoc. Prof Shereen Elazzazy

  44. Law, Culture, and Fear: A Qualitative Study of Health Professionals’ Perceptions of Narcotic Use Related to Cancer Pain

    Article • Journal of Pain & Palliative Care Pharmacotherapy, February 2020, Taylor & Francis

    Assoc. Prof Shereen Elazzazy

  45. Abstracts

    Article • Journal of Oncology Pharmacy Practice, December 2019, SAGE Publications

    Assoc. Prof Shereen Elazzazy

  46. Perceptions and expectations of health care providers towards clinical pharmacy services at a tertiary cancer centre in Qatar

    Article • Journal of Oncology Pharmacy Practice, November 2019, SAGE Publications

    Assoc. Prof Shereen Elazzazy , Nabil E. Omar

  47. IMPACT OF OLAPARIB USE ON CANCER PATIENTS IN QATAR: MEDICATION USE EVALUATION

    Article • July 2019, Morressier

    Assoc. Prof Shereen Elazzazy

  48. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia – Case report and literature review

    Article • Journal of Oncology Pharmacy Practice, June 2019, SAGE Publications

    Assoc. Prof Shereen Elazzazy

  49. BPI19-016: Evaluation of the Use of a Single Dose Rasburicase in Prophylaxis and Management of Tumor Lysis Syndrome (TLS) Among Cancer Patients in Qatar

    Article • Journal of the National Comprehensive Cancer Network, March 2019, Harborside Press, LLC

    Assoc. Prof Shereen Elazzazy

  50. QIM19-115: Barriers and Trends in Cancer Patients` Pain Management in Qatar: A Randomized Cohort Prospective Study

    Article • Journal of the National Comprehensive Cancer Network, March 2019, Harborside Press, LLC

    Assoc. Prof Shereen Elazzazy

  51. QIM19-116: Barriers and Trends in Cancer Patients’ referrals to Pain Management in Qatar: A Randomized Cohort Prospective Study

    Article • Journal of the National Comprehensive Cancer Network, March 2019, Harborside Press, LLC

    Assoc. Prof Shereen Elazzazy

  52. Practice implications of an antimicrobial stewardship intervention in a tertiary care teaching hospital, Qatar

    Article • Eastern Mediterranean Health Journal, March 2019, World Health Organization Regional Office for the Eastern Mediterranean (WHO/EMRO)

    Assoc. Prof Shereen Elazzazy

  53. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study

    Article • Journal of Oncology Pharmacy Practice, January 2019, SAGE Publications

    Assoc. Prof Shereen Elazzazy

  54. Cost-Analysis of Posaconazole for Prophylaxis Against Fungal Infections in Patients with Hematological Malignancies in Qatar

    Article • Value in Health, September 2018, Elsevier

    Assoc. Prof Shereen Elazzazy

  55. Acupuncture for cancer-related fatigue in lung cancer patients: methodological and statistical issues

    Article • Supportive Care in Cancer, July 2018, Springer Science + Business Media

    Assoc. Prof Shereen Elazzazy

  56. Abstracts of the MASCC/ISOO 2017 Annual Meeting

    Article • Supportive Care in Cancer, April 2017, Springer Science + Business Media

    Dr Omotayo Francis Fagbule, Assoc. Prof Shereen Elazzazy

  57. A Review of Clinical Outcomes Associated with Two Meropenem Dosing Strategies

    Article • Drugs in R&D, January 2017, Springer Science + Business Media

    Assoc. Prof Shereen Elazzazy

  58. Digital signal processing-based techniques: Providing pharmacists with computerized procedures for investigations

    Article • Journal of Clinical Trials, January 2017, OMICS Publishing Group

    Dr Norbert Ikechukwu Nwankwo, Assoc. Prof Shereen Elazzazy

  59. Substandard Amoxicillin in Sierra Leone

    Article • Pharmaceutical Regulatory Affairs Open Access, January 2017, OMICS Publishing Group

    Assoc. Prof Shereen Elazzazy

  60. END OF LIFE CARE FOR HAEMATOLOGIC MALIGNANCIES: A RETROSPECTIVE COHORT STUDY FROM THE STATE OF QATAR.

    Article • International Journal of Advanced Research, November 2016, International Journal Of Advanced Research

    Assoc. Prof Shereen Elazzazy

  61. Base deficit and serum lactate concentration in patients with post traumatic convulsion

    Article • Asian Journal of Neurosurgery, January 2016, Medknow

    Professor Ayman El-Menyar, Assoc. Prof Shereen Elazzazy

  62. Clinical pharmacokinetics: perceptions of hospital pharmacists in Qatar about how it was taught and how it is applied

    Article • International Journal of Clinical Pharmacy, September 2015, Springer Science + Business Media

    Assoc. Prof Shereen Elazzazy

  63. Clinical Outcomes of Implementing Evidence-Based Practice on Venous Thromboembolism Prevention for Cancer Patients In Qatar, A Retrospective Study

    Article • Clinical Therapeutics, August 2015, Elsevier

    Assoc. Prof Shereen Elazzazy

  64. Determination of Predictive Factors Associated With Poor Seizure Control In Cancer Patients

    Article • Clinical Therapeutics, August 2015, Elsevier

    Assoc. Prof Shereen Elazzazy

  65. A Grave Outcome of Posterior Reversible Encephalopathy Syndrome in a Patient Receiving Avastin (Bevacizumab) for Metastatic High-Grade Serous Ovarian Cancer

    Article • Case Reports in Oncology, July 2015, Karger Publishers

    Assoc. Prof Shereen Elazzazy

  66. Cyclophosphamide-induced symptomatic hyponatremia, a rare but severe side effect: a case report

    Article • OncoTargets and Therapy, September 2014, Taylor & Francis

    Assoc. Prof Shereen Elazzazy

  67. Point prevalence survey of antimicrobial utilization in oncology patients

    Article • The Journal of Infection in Developing Countries, December 2013, Journal of Infection in Developing Countries

    Assoc. Prof Shereen Elazzazy

  68. Nutrition therapy for critically ill and injured patients

    Article • European Journal of Trauma and Emergency Surgery, March 2013, Springer Science + Business Media

    Assoc. Prof Shereen Elazzazy

  69. Severe hypophosphatemia induced after first cycle of the ESHAP protocol for Hodgkin's lymphoma: a case report

    Article • International Medical Case Reports Journal, January 2013, Dove Medical Press

    Assoc. Prof Shereen Elazzazy

  70. Toxic Epidermal Necrolysis Associated with Antiepileptic Drugs and Cranial Radiation Therapy

    Article • Case Reports in Oncological Medicine, January 2013, Wiley

    Assoc. Prof Shereen Elazzazy

  71. Point prevalence survey of antibiotic utilization in oncology patients

    Article • Qatar Foundation Annual Research Forum Proceedings, October 2012, QScience

    Assoc. Prof Shereen Elazzazy

  72. Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone

    Article • International Medical Case Reports Journal, September 2012, Taylor & Francis

    Assoc. Prof Shereen Elazzazy

  73. MP-17.24

    Article • Urology, November 2006, Elsevier

    Assoc. Prof Shereen Elazzazy

  74. Table_1.docx

    Article • Frontiers

    Assoc. Prof Shereen Elazzazy